Metabolic Syndrome: Updates on Pathophysiology and Management in 2021

Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin resistance, atherogenic dyslipidemia, central obesity, and hypertension. We also discuss the current and latest knowledge about the histopathology and pathophysiology of the disease.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 The pathogenesis of MetS encompasses multiple genetic and acquired entities that fall under the umbrella of insulin resistance and chronic low-grade inflammation.
• 2 If left untreated, MetS is significantly associated with an increased risk of developing diabetes and cardiovascular diseases (CVDs).
• 3 Given that CVDs constitute by far the leading cause of morbidity and mortality worldwide, it has become essential to investigate the role played by MetS in this context to reduce the heavy burden of the disease.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: